Sayora Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.45 M
- Company Age 36 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 6.20 M
- Satisfied Charges ₹ 0.58 M
- Revenue Growth -44.35%
- Profit Growth -88.42%
- Ebitda -38.93%
- Net Worth 3.81%
- Total Assets -10.06%
About Sayora Pharma
Sayora Pharma Private Limited (SPPL) is a Private Limited Indian Non-Government Company incorporated in India on 12 December 1988 and has a history of 36 years and one month. Its registered office is in Chandigarh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.45 M.
The company currently has active open charges totaling ₹6.20 M. The company has closed loans amounting to ₹0.58 M, as per Ministry of Corporate Affairs (MCA) records.
Devinder Syal and Rashmi Syal serve as directors at the Company.
Company Details
-
Location
Chandigarh, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24211CH1988PTC008896
-
Company No.
008896
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
12 Dec 1988
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Chandigarh
Industry
Who are the key members and board of directors at Sayora Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Devinder Syal
|
Managing Director | 12-Dec-1988 | Current |
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Rashmi Syal
|
Director | 01-Jan-1990 | Current |
Financial Performance of Sayora Pharma.
Sayora Pharma Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 44.35% decrease. The company also saw a substantial fall in profitability, with a 88.42% decrease in profit. The company's net worth moved up by a moderate rise of 3.81%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sayora Pharma?
Unlock access to Sayora Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹6.20 M
₹0.58 M
Charges Breakdown by Lending Institutions
- Canara Bank : 0.62 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 25 Sep 2009 | Canara Bank | ₹6.20 M | Open |
| 13 Jun 2014 | Canara Bank | ₹0.58 M | Satisfied |
How Many Employees Work at Sayora Pharma?
Sayora Pharma has a workforce of 3 employees as of Mar 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sayora Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sayora Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.